The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.

Documenti analoghi

• Ecstasy cannot be assumed to be 3,4-methylenedioxyamphetamine (MDMA)
  di: Green, AR, et al.
  Pubblicazione: (2012)
• The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy') to rats
  di: Mechan, Annis O, et al.
  Pubblicazione: (2002)
• Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy') administration
  di: Colado, M I, et al.
  Pubblicazione: (1999)
• A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy') on dopamine neurones in mouse brain
  di: Colado, M Isabel, et al.
  Pubblicazione: (2001)
• Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity
  di: O'Hearn, E, et al.
  Pubblicazione: (1988)